Camrelizumab

Monoclonal antibody

Also known as SHR-1210

Approvedregulatory verdict

Evidence outlook

Approved: Recurrent or metastatic cervical cancer after platinum-based chemotherapy, without prior... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USNasopharyngeal Carcinoma · Phase 3 · investigational in the USCervical Cancer · Phase 2/3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US

Also approved (8)
CN
  • Recurrent or metastatic cervical cancer after platinum-based chemotherapy, without prior bevacizumab, with famitinib (conditional approval)
  • First-line unresectable or metastatic hepatocellular carcinoma, with apatinib
  • First-line locally advanced or metastatic squamous NSCLC, with carboplatin + paclitaxel
  • First-line locally relapsed or metastatic nasopharyngeal carcinoma, with cisplatin + gemcitabine
  • Advanced nasopharyngeal carcinoma progressed after or intolerable to second-line or later chemotherapy
  • First-line unresectable locally advanced or metastatic EGFR-negative, ALK-negative non-squamous NSCLC, with pemetrexed + carboplatin
  • Advanced hepatocellular carcinoma after sorafenib and/or oxaliplatin-containing chemotherapy
  • Relapsed or refractory classic Hodgkin lymphoma after at least two systematic therapies (conditional approval; first approval)
Product first approved 2019hengrui.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (45)
Gastric Cancer
NCT05610332 · Fujian Medical University
2022-11-01 – 2027-11-01 · Locally Advanced Gastric Cancer
What this study did
NCT04342910 · Jiangsu HengRui Medicine Co., Ltd.
2020-09-21 – 2026-09-01 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT06172205 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2029-07-31 · BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
What this study did
NCT06485466 · Guohui Xu
2024-08-10 – 2028-06-30 · Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
What this study did
NCT05738616 · Wen Tianfu
2024-05-10 – 2027-12-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT04639180 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-01 – 2026-07-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05320692 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-09 – 2026-07-30 · Hepatocellular Carcinoma
What this study did
NCT05313282 · Sun Yat-sen University
2022-06-15 – 2025-06-01 · C-staged Hepatocellular Carcinoma in BCLC Classification
What this study did
NCT03605706 · Jiangsu HengRui Medicine Co., Ltd.
2019-05-31 – 2023-12 · Advanced Hepatocellular Carcinoma
What this study did
NCT04985136 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-26 – 2021-12-29 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
Nasopharyngeal Carcinoma
NCT06669611 · Sun Yat-sen University
2024-11-27 – 2029-11-20 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT06438627 · XIANG YANQUN
2024-05-30 – 2029-05-30 · Nasopharyngeal Carcinoma
What this study did
NCT04453826 · Sun Yat-sen University
2020-09-01 – 2028-09 · Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
What this study did
NCT05772208 · Fudan University
2022-01-01 – 2028-01-01 · Nasopharyngeal Carcinoma
What this study did
NCT05854849 · Sun Yat-sen University
2023-05-01 – 2027-12-01 · Nasopharyngeal Carcinoma
What this study did
NCT03427827 · Sun Yat-sen University
2018-07-02 – 2026-02 · Nasopharyngeal Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT04768075 · Guangdong Association of Clinical Trials
2021-05-28 – 2026-04-30 · Non-Small-Cell Lung Cancer
What this study did
NCT05042375 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-08 – 2025-12-31 · Non-small Cell Lung Cancer
What this study did
NCT04203485 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-15 – 2022-05-31 · PD-L1 Positive Non-small Cell Lung Cancer
What this study did
NCT03668496 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-09 – 2021-12-31 · Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody, Chemotherapy Effect
What this study did
Other / comorbidity
NCT07432087 · Yue He, MD
2026-02-01 – 2033-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT07267806 · Linhui Peng
2025-10-31 – 2032-10 · Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
What this study did
NCT06533384 · Guangdong Provincial People's Hospital
2024-08-01 – 2030-12-31 · Triple-negative Breast Cancer
What this study did
NCT05043688 · Zhigang Li
2021-09-01 – 2030-12-31 · Resectable Esophageal Squamous Cell Carcinoma
What this study did
NCT07948317 · Xuekui Liu
2027-01-01 – 2030-01-01 · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer
What this study did
NCT06229041 · Peking University Cancer Hospital & Institute
2023-03-29 – 2029-10-01 · Rectal Cancer
What this study did
NCT06889688 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-02-21 – 2029-06-01 · Breast Cancer Stage IV, Triple -Negative Breast Cancer
What this study did
NCT04928807 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-07-20 – 2028-03-20 · Rectal Cancer
What this study did
NCT05999149 · Fudan University
2023-08-20 – 2027-08-30 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT05789043 · Peking University Cancer Hospital & Institute
2023-03-21 – 2027-02-15 · Acral Melanoma
What this study did
NCT05760378 · Fudan University
2023-03-17 – 2027-01-01 · Triple-Negative Breast Cancer
What this study did
NCT05798793 · Hospital of Stomatology, Wuhan University
2023-11-21 – 2026-10-01 · Oral Squamous Cell Carcinoma
What this study did
NCT04613674 · Jiangsu HengRui Medicine Co., Ltd.
2020-12-09 – 2024-03-05 · Triple Negative Breast Cancer
What this study did
NCT04342936 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-17 – 2023-12-01 · Classical Hodgkin Lymphoma
What this study did
NCT04426955 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-30 – 2023-12 · Esophageal Cancer
What this study did
NCT05134194 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-01-17 – 2022-12-15 · Triple Negative Breast Cancer
What this study did
NCT03691090 · Jiangsu HengRui Medicine Co., Ltd.
2018-12-03 – 2022-04-30 · Advanced Esophageal Cancer
What this study did
NCT04490421 · Fuzhou General Hospital
2020-08-01 – 2022-02-01 · Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors
What this study did
NCT03099382 · Jiangsu HengRui Medicine Co., Ltd.
2017-05-05 – 2019-05-06 · Esophageal Carcinoma
What this study did
Phase 2/3 (13)
Cervical Cancer
NCT06288373 · Tongji Hospital
2024-04-22 – 2031-03-01 · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
What this study did
Gastric Cancer
NCT04208347 · Ruijin Hospital
2019-12-18 – 2027-12 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT06739317 · Sun Yat-sen University
2025-01-01 – 2031-06-30 · Unresectable Hepatocellular Carcinoma (HCC)
What this study did
NCT06796803 · Shanghai Zhongshan Hospital
2025-02-20 – 2030-02-28 · Potentially Resectable Hepatocellular Carcinoma
What this study did
NCT05062837 · Guangxi Medical University
2021-06-01 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT04521153 · Shanghai Zhongshan Hospital
2021-03-25 – 2026-03-01 · Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
What this study did
NCT04909866 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-01-01 – 2022-12-01 · Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT04803539 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-01 – 2033-09-01 · Breast Cancer
What this study did
NCT07589244 · Guangzhou Virotech Pharmaceutical Co., Ltd.
2026-05-13 – 2029-06-30 · HCC
What this study did
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06361888 · Hutchmed
2024-05-08 – 2028-05-31 · Metastatic Pancreatic Cancer
What this study did
NCT04907344 · Tianjin Medical University Cancer Institute and Hospital
2021-06-15 – 2025-06-30 · Triple Negative Breast Cancer
What this study did
NCT04510610 · Chinese PLA General Hospital
2019-09-01 – 2025-01-01 · Hodgkin Lymphoma
What this study did
Phase 2 (331)
Cervical Cancer
NCT06288360 · Tongji Hospital
2024-09-12 – 2030-12-12 · Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
What this study did
NCT06289062 · Tongji Hospital
2024-05-08 – 2030-12-01 · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
What this study did
NCT07167160 · Women's Hospital School Of Medicine Zhejiang University
2025-03-10 – 2029-12-31 · Cervical Cancer, Immunochemotherapy
What this study did
NCT07627620 · Hunan Cancer Hospital
2026-06-30 – 2029-03-30 · Cervical Cancer
What this study did
NCT07143292 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-11-30 – 2028-06-30 · Cervical Cancer Metastatic, Cervical Cancer Recurrent
What this study did
NCT05311566 · Lei Li
2022-03-27 – 2026-03-27 · Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy, Immune Checkpoint Inhibitor, Survival Outcomes, Adverse Events, Early Stage Cervical Cancer, Locally Advanced Cervical Cancer
What this study did
NCT04680988 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-05 – 2025-07-07 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT05234905 · Zhejiang Cancer Hospital
2022-03 – 2024-12 · Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab
What this study did
NCT04884906 · Tianjin Medical University Cancer Institute and Hospital
2020-11-01 – 2024-11-01 · Locally Advanced Cervical Cancer
What this study did
NCT05290935 · Lei Li
2022-03-13 – 2024-03-13 · Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors, Anti-PD-1 Antibody, Albumin-bound Paclitaxel
What this study did
NCT04974944 · Sun Yat-Sen University Cancer Center
2021-07-30 – 2024-01-08 · Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
What this study did
NCT05151549 · Hunan Cancer Hospital
2021-12-01 – 2023-12-12 · Cervical Cancer
What this study did
NCT04974827 · Hunan Cancer Hospital
2021-05-20 – 2023-05-20 · Cervical Cancer
What this study did
NCT03827837 · Jiangsu HengRui Medicine Co., Ltd.
2019-01-23 – 2022-12 · Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
What this study did
NCT03816553 · Sun Yat-sen University
2019-01-19 – 2022-08-31 · Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
What this study did
NCT04188860 · Lei Li
2019-12-06 – 2022-03-06 · Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody, Immunotherapy
What this study did
Gastric Cancer
NCT07026149 · Ruijin Hospital
2025-06-08 – 2030-05-31 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06693128 · Ruijin Hospital
2024-11-21 – 2027-12-31 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06711471 · LIN YANG
2024-11-14 – 2027-11-13 · Gastric Cancer Adenocarcinoma Metastatic
What this study did
NCT05524974 · Fujian Medical University
2022-09-01 – 2027-09-01 · Locally Advanced Gastric Cancer
What this study did
NCT03950271 · Henan Cancer Hospital
2020-01-20 – 2026-12-31 · Gastric Cancer
What this study did
NCT07320586 · Shandong Tumor Hospital
2021-03-01 – 2026-12-31 · Gastric Cancer, Second-line Therapy
What this study did
NCT05602935 · The Second Affiliated Hospital of Fujian Medical University
2020-09-16 – 2026-12-30 · Stomach Neoplasms, Digestive System Neoplasms, Neoplasms, Digestive System Diseases, Stomach Diseases, Neoplasms by Site
What this study did
NCT04515615 · Yu jiren
2020-09-09 – 2026-03-29 · Gastric Cancer Stage III
What this study did
NCT05669807 · Zhejiang Cancer Hospital
2022-12 – 2025-11 · Second Line Treatment of Gastric Cancer
What this study did
NCT05184946 · The Second Affiliated Hospital of Shandong First Medical University
2021-10-09 – 2025-10-08 · Gastric Cancer
What this study did
NCT04781686 · Zhou Fuxiang
2021-05-14 – 2025-08 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05410847 · Hebei Medical University
2022-06-30 – 2025-06-30 · Gastric Cancer
What this study did
NCT04195828 · Fujian Medical University
2020-06-18 – 2025-03-24 · Advanced Gastric Cancer
What this study did
NCT04510064 · Fudan University
2021-01-06 – 2024-07-31 · Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
What this study did
NCT03939962 · Henan Cancer Hospital
2019-07-24 – 2024-05-30 · Gastric Cancer
What this study did
NCT05070598 · Shengjing Hospital
2021-09-07 – 2024-03-30 · HER2-positive Gastric Cancer
What this study did
NCT04631757 · Tianjin Medical University Cancer Institute and Hospital
2020-12-15 – 2023-12-31 · Gastric Cancer
What this study did
NCT04294784 · Huazhong University of Science and Technology
2020-04-03 – 2023-11-30 · Gastric Cancer, GastroEsophageal Cancer
What this study did
NCT05342389 · Sixth Affiliated Hospital, Sun Yat-sen University
2022-05-01 – 2023-11-01 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05095636 · Fudan University
2021-03-17 – 2023-09 · Gastric Cancer, Metastasis
What this study did
NCT05545436 · Third Affiliated Hospital, Sun Yat-Sen University
2022-09-20 – 2023-06 · Locally Advanced Gastric Cancer
What this study did
NCT04694183 · Quan Wang
2020-08-17 – 2023-05-06 · Stomach Neoplasms
What this study did
NCT04367025 · Chinese PLA General Hospital
2020-05 – 2023-05 · Gastric Cancer
What this study did
NCT04258644 · Beijing Friendship Hospital
2020-03-01 – 2023-02-28 · Gastric Cancer
What this study did
NCT04792515 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2022-12-31 · Locally Advanced Gastric Cancer
What this study did
NCT04152889 · RenJi Hospital
2020-04-14 – 2022-12 · Gastric Cancer Stage III
What this study did
NCT04345783 · Beijing Friendship Hospital
2018-01-01 – 2022-06-30 · Gastric Cancer
What this study did
NCT03755440 · Sun Yat-sen University
2018-12-01 – 2020-12-31 · Gastric Cancer Stage IV, EBV
What this study did
NCT03472365 · Jiangsu HengRui Medicine Co., Ltd.
2018-04-02 – 2020-11-25 · Gastric Cancer, GastroEsophageal Cancer
What this study did
Hepatocellular Carcinoma
NCT07328009 · Fudan University
2026-01-19 – 2029-01-15 · Hepato Cellular Carcinoma (HCC)
What this study did
NCT07324473 · First Affiliated Hospital of Chongqing Medical University
2026-01-01 – 2029-01-01 · Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
What this study did
NCT07314372 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-02-01 – 2028-12 · Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
What this study did
Phase 1/2 (40)
Gastric Cancer
NCT05101616 · Shanghai Minimally Invasive Surgery Center
2022-07-01 – 2027-01-01 · Gastric Cancer
What this study did
NCT04572542 · The First Affiliated Hospital of Xiamen University
2020-01-01 – 2022-06-01 · Locally Advanced or Metastatic Gastric Adenocarcinoma
What this study did
NCT04182724 · Chinese PLA General Hospital
2019-11-12 – 2022-05-12 · Advanced Gastric Cancer
What this study did
NCT04067986 · Zhongshan Hospital Xiamen University
2019-08-20 – 2021-10-31 · Colorectal Cancer Recurrent
What this study did
NCT04286711 · China Medical University, China
2020-03 – 2021-06 · Advanced Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT06124001 · CNBG-Virogin Biotech (Shanghai) Ltd.
2023-11-30 – 2026-06-30 · Primary Hepatocellular Carcinoma
What this study did
NCT05924997 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2026-06-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT04443309 · Peking Union Medical College Hospital
2020-09-11 – 2024-08 · Hepatocellular Carcinoma
What this study did
NCT04997850 · Xinrui Zhu,MD
2020-10-01 – 2024-01-31 · Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade
What this study did
NCT05042336 · Sichuan University
2021-09-01 – 2023-10-01 · Carrelizumab Plus Lenvatinib Combined With TACE, Borderline Resectable Hepatocellular Carcinoma
What this study did
NCT04035876 · Zhejiang University
2019-07-16 – 2021-12-31 · Hepatocellular Carcinoma, Liver Transplant
What this study did
NCT02942329 · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
2016-10 – 2018-10 · Gastric Cancer, Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04133337 · Sichuan Cancer Hospital and Research Institute
2019-11-01 – 2021-06 · Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms, Non-small-cell Lung Cancer
What this study did
NCT03601598 · Harbin Medical University
2018-07-30 – 2020-07-30 · CRC, HCC, NSCLC
What this study did
Other / comorbidity
NCT05981001 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-08-01 – 2035-04-30 · Breast Neoplasms
What this study did
NCT07587034 · Shanghai Zhongshan Hospital
2026-06 – 2029-12 · Liver Cancer
What this study did
NCT07662681 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2026-07-01 – 2029-07-01 · Head and Neck Cancer
What this study did
NCT05983237 · Jun Guo
2023-08-15 – 2027-12-31 · Melanoma
What this study did
NCT07161791 · Harbin Medical University
2025-09-15 – 2027-12-31 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT06376721 · Beijing Tongren Hospital
2024-04-14 – 2027-10-31 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma
What this study did
NCT04706598 · Fudan University
2021-06-09 – 2026-12 · Urinary Bladder Neoplasms, Immunotherapy
What this study did
NCT05176002 · Fujian Medical University Union Hospital
2021-11-10 – 2026-11 · Esophageal Neoplasm, Immunotherapy, Radiotherapy
What this study did
NCT04481763 · Jiangxi Provincial Cancer Hospital
2020-07-14 – 2026-10-01 · Triple-Negative Breast Cancer
What this study did
NCT06010212 · The First Affiliated Hospital with Nanjing Medical University
2023-08-25 – 2026-07-01 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05742750 · Sun Yat-sen University
2023-04-27 – 2026-05-30 · Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
What this study did
NCT04337606 · Chinese PLA General Hospital
2020-04-04 – 2026-04-04 · Non Hodgkin Lymphoma
What this study did
NCT05559008 · Ruijin Hospital
2022-09-30 – 2026-01-26 · Peripheral T Cell Lymphoma
What this study did
NCT04506138 · Zhejiang Cancer Hospital
2020-08-11 – 2025-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05218889 · Chinese PLA General Hospital
2021-08-04 – 2025-06 · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
What this study did
NCT05330065 · The First Affiliated Hospital of Zhengzhou University
2022-08-01 – 2024-08-31 · Malignant Pleural Effusion
What this study did
NCT04929652 · Jiangsu Cancer Institute & Hospital
2021-06-01 – 2024-06 · Advanced Colorectal Cancer
What this study did
NCT04231552 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2019-11-10 – 2023-09-30 · Rectal Cancer, Radiotherapy, Immunotherapy
What this study did
NCT04476459 · Huiqiang Huang
2020-07-23 – 2023-08-01 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
What this study did
NCT04298320 · Yanqiao Zhang
2020-03-15 – 2023-02-28 · Colorectal Cancer
What this study did
NCT04213898 · Henan Cancer Hospital
2020-01 – 2023-01 · Triple-negative Breast Cancer
What this study did
NCT04201990 · ShiYue Li
2019-12 – 2022-12 · Lung Cancer
What this study did
NCT04044378 · Peking University People's Hospital
2019-08-15 – 2022-09-30 · Effect of Drugs, Progression, Pediatric Cancer
What this study did
NCT04202978 · Zhongshan Hospital Xiamen University
2020-03-01 – 2021-11-01 · Hepatic Metastasis of Colorectal Cancer
What this study did
NCT03171220 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2017-06-01 – 2020-12-31 · Advanced Malignant Solid Tumor
What this study did
NCT03346642 · Chinese PLA General Hospital
2017-05-01 – 2019-10-01 · Primary Mediastinal Large B-cell Lymphoma
What this study did
Phase 1 (28)
Cervical Cancer
NCT04508686 · Ruijin Hospital
2020-08-01 – 2024-08-01 · Advanced Cervical Cancer
What this study did
Hepatocellular Carcinoma
NCT05031949 · Zhang Bi Xiang, MD
2021-10-30 – 2025-06-30 · Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable, Hyperbaric Oxygen Therapy
What this study did
NCT04564313 · Third Affiliated Hospital, Sun Yat-Sen University
2020-09-21 – 2023-07 · Hepatocellular Carcinoma, Liver Transplantation
What this study did
Nasopharyngeal Carcinoma
NCT03121716 · Jiangsu HengRui Medicine Co., Ltd.
2017-04-26 – 2020-07-31 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT03527251 · Sun Yat-sen University
2018-05-15 – 2019-12-31 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06121557 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-01 – 2031-12-31 · Breast Neoplasms
What this study did
NCT06654297 · West China Hospital
2024-10-27 – 2027-02-07 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06530082 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-12-01 – 2027-01-01 · Breast Neoplasms
What this study did
NCT06326736 · Jinling Hospital, China
2024-04 – 2026-12 · Pancreatic Cancer
What this study did
NCT06109207 · West China Hospital
2023-10-31 – 2025-10-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04932187 · Ruijin Hospital
2021-08-01 – 2025-07-01 · Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
What this study did
NCT04074564 · HRYZ Biotech Co.
2019-11-22 – 2024-12-05 · Sarcoma
What this study did
NCT05643417 · Fudan University
2022-12 – 2024-10 · Metastatic Liver Cancer
What this study did
NCT04510818 · Ruijin Hospital
2020-08-01 – 2024-08-01 · Head and Neck Cancer, Esophageal Squamous Cancer
What this study did
NCT05429398 · Shanghai YingLi Pharmaceutical Co. Ltd.
2022-06-30 – 2024-05-30 · Advanced Solid Tumor
What this study did
NCT05001412 · Zhou Chengzhi
2021-01-27 – 2024-01-25 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT04393506 · Shanghai Jiao Tong University School of Medicine
2020-04-23 – 2023-11-10 · Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy
What this study did
NCT05799183 · Jiangsu HengRui Medicine Co., Ltd.
2023-07-04 – 2023-10-12 · Advanced Tumors
What this study did
NCT03491631 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-20 – 2023-09 · Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
What this study did
NCT05198817 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-02-22 – 2023-06-30 · Advanced Malignant Tumors
What this study did
NCT04625894 · Fudan University
2020-12 – 2023-06 · Oligometastatic Gastrointestinal Cancer
What this study did
NCT05019534 · West China Hospital
2021-08-15 – 2022-12-01 · BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
What this study did
NCT03871855 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-28 – 2021-06-21 · Advanced Solid Tumor
What this study did
NCT03945604 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-04 – 2021-02-09 · Triple Negative Breast Cancer
What this study did
NCT02738489 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-13 – 2020-01-08 · Advanced Melanoma
What this study did
NCT02721589 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-06 – 2019-11-17 · Advanced Solid Tumors
What this study did
NCT03182673 · Jiangsu HengRui Medicine Co., Ltd.
2017-07-24 – 2019-06-12 · Solid Tumor
What this study did
NCT02742935 · Jiangsu HengRui Medicine Co., Ltd.
2016-04-27 – 2019-05-06 · Solid Tumor, Breast Cancer, Gastrointestinal Cancer
What this study did
Phase 4 (1)
Early phase / not applicable (33)
Cervical Cancer
NCT07466901 · Jin LI
2026-04-01 – 2030-08-31 · Cervical Cancer, Radical Surgery, Adjuvant Therapy
What this study did
Gastric Cancer
NCT04889768 · Zhejiang Cancer Hospital
2021-07-31 – 2025-07-31 · Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
What this study did
NCT05715632 · Tang-Du Hospital
2023-02-01 – 2025-03-01 · Gastric Cancer
What this study did
NCT04675866 · Henan Cancer Hospital
2020-08-17 – 2023-12-31 · Advanced Gastric Adenocarcinoma
What this study did
NCT04174339 · Fujian Cancer Hospital
2019-12-10 – 2021-05-02 · Advanced Gastric Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT04559607 · Zhongda Hospital
2020-09-11 – 2026-01-31 · Hepatocellular Carcinoma
What this study did
NCT06061276 · Sun Yat-sen University
2024-05-20 – 2025-12-30 · Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab, Lenvatinib
What this study did
NCT04487704 · First Affiliated Hospital Xi'an Jiaotong University
2020-04-07 – 2025-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT03722875 · Shanghai Zhongshan Hospital
2018-12-01 – 2020-03-01 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07053215 · The First Hospital of Hebei Medical University
2020-12-01 – 2024-12-01 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT04970043 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2021-07-31 – 2024-07-30 · Lung Cancer Stage II
What this study did
NCT04950400 · Beijing Chest Hospital
2021-07-07 – 2024-04-04 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07491822 · Tianjin Medical University Cancer Institute and Hospital
2026-03-25 – 2031-03-15 · TNBC
What this study did
NCT06048926 · The First Affiliated Hospital with Nanjing Medical University
2022-07-30 – 2028-07-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05772273 · The First Affiliated Hospital of Soochow University
2023-03-15 – 2027-12-31 · Acute Myeloid Leukemia
What this study did
NCT05202314 · Beijing Chao Yang Hospital
2021-12-12 – 2026-12-30 · Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction, Immunotherapy
What this study did
NCT06636591 · Fudan University
2024-12-23 – 2026-06-30 · Breast Cancer Female, HER2-negative Breast Cancer
What this study did
NCT05380986 · Henan Cancer Hospital
2022-05-20 – 2025-05-01 · Solid Tumor
What this study did
NCT05583383 · Henan Cancer Hospital
2022-03-31 – 2025-03-31 · Advanced Gastric Adenocarcinoma
What this study did
NCT04366128 · Rong Tao
2020-04-25 – 2024-12-30 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT05697237 · First Affiliated Hospital Xi'an Jiaotong University
2023-01 – 2024-12 · Cholangiocarcinoma
What this study did
NCT04782089 · Qilu Hospital of Shandong University
2021-05-06 – 2024-06-01 · Small Cell Lung Cancer
What this study did
NCT05600998 · Peking University Third Hospital
2022-10-30 – 2024-02-28 · Ovarian Clear Cell Carcinoma
What this study did
NCT05050760 · Xijing Hospital
2021-09-01 – 2023-12 · ESCC
What this study did
NCT04420130 · Yanqiao Zhang
2020-08-01 – 2023-08-01 · Pancreatic Cancer, Liver Metastasis
What this study did
NCT04741490 · Fuzhou General Hospital
2021-02 – 2023-08 · Esophageal Squamous Cell Carcinomas
What this study did
NCT04181645 · RenJi Hospital
2019-06-29 – 2023-05-01 · Pancreatic Cancer Stage IV
What this study did
NCT04654403 · The First Affiliated Hospital of Zhengzhou University
2022-01-01 – 2022-12-31 · Esophageal Cancer
What this study did
NCT04507750 · Qianfoshan Hospital
2020-08-10 – 2022-08-30 · Immune Checkpoint Inhibition
What this study did
NCT03671265 · Tianjin Medical University Cancer Institute and Hospital
2018-09-17 – 2021-09-01 · Esophageal Cancer
What this study did
NCT03222440 · Tianjin Medical University Cancer Institute and Hospital
2017-07-19 – 2019-11-01 · Esophageal Cancer
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (3)
Hepatocellular Carcinoma
NCT07309419 · Shanghai Zhongshan Hospital
2025-12-22 – 2030-06-30 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT05576272 · Qilu Pharmaceutical Co., Ltd.
2022-05-19 – 2024-12-30 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06335355 · Shanghai Shengdi Pharmaceutical Co., Ltd
2024-03 – 2030-10 · Non-squamous Non-small Cell Lung Cancer
What this study did
Appears in other studies (16)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Hepatocellular Carcinoma
NCT05613478 · The First Affiliated Hospital with Nanjing Medical University
2023-01-31 – 2027-11-01 · Hepatocellular Carcinoma, Immunotherapy, Preoperative
What this study did
NCT05198609 · Sun Yat-sen University
2022-01-17 – 2026-07-01 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT04944914 · Sun Yat-sen University
2021-06-01 – 2028-06-01 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04619433 · Jiangsu HengRui Medicine Co., Ltd.
2021-02-01 – 2025-08-16 · Non-squamous Non-small-cell Lung Cancer
What this study did
Other / comorbidity
NCT05049681 · Feng Wang
2021-12-05 – 2023-06-30 · Esophageal Cancer
What this study did
Phase 2 (8)
Hepatocellular Carcinoma
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT04930315 · Zhejiang University
2021-09-15 – 2026-04-30 · Hepatocellular Carcinoma
What this study did
Nasopharyngeal Carcinoma
NCT04830267 · Chongqing University Cancer Hospital
2021-03-01 – 2026-08-01 · Nasopharyngeal Carcinoma
What this study did
Other / comorbidity
NCT07791602 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-06-12 – 2032-12 · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
What this study did
NCT06055166 · Chongqing University Cancer Hospital
2023-11-01 – 2026-05-31 · PARP Inhibitor for Esophageal Squamous Cell Carcinoma
What this study did
NCT05222035 · Sun Yat-sen University
2022-01-24 – 2023-06-01 · PD-1 Inhibitor, G-CSF
What this study did
NCT03987698 · Tianjin Medical University Cancer Institute and Hospital
2019-06-01 – 2022-06-01 · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT06276933 · Tongji University
2024-02-22 – 2026-11-22 · Lung Cancer, Camrelizumab
What this study did
Early phase / not applicable (2)
Hepatocellular Carcinoma
NCT05339581 · RenJi Hospital
2022-05-20 – 2024-05-31 · Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications
What this study did
Other / comorbidity
NCT07067450 · Sichuan University
2025-07-20 – 2026-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Camrelizumab: this drugPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
TagitanlimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)Phase 2Antibody–drug conjugateTissue Factor (TF)Weak signalFeatured results are dose-finding only in this race
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 113 furthest-along competitors are listed; 500 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(81 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Camrelizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (15)
November 2026 (1)
Phase 2Soft Tissue Sarcoma (STS), OsteosarcomaRecruiting
Est. primary completion 2026-11-30 · NCT07602049 · CT.gov ↗
What to watch
December 2026 (14)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07107217 · CT.gov ↗
What to watch
Phase 2/3Gastric CancerActive not recruiting
Est. primary completion 2026-12 · NCT04208347 · CT.gov ↗
What to watch
Phase 2Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT07530094 · CT.gov ↗
What to watch
Phase 2Gestational Trophoblastic NeoplasiaRecruiting
Est. primary completion 2026-12-01 · NCT05139095 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07143292 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT05062837 · CT.gov ↗
What to watch
Phase 1Breast NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT06121557 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT05983237 · CT.gov ↗
What to watch
Phase 1/2Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07161791 · CT.gov ↗
What to watch
Phase 2Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06831175 · CT.gov ↗
What to watch
Phase 2Hepatocellulcar CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07238881 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12-31 · NCT07167160 · CT.gov ↗
What to watch
Phase 2ESCCRecruiting
Est. primary completion 2026-12-31 · NCT07808853 · CT.gov ↗
What to watch
Phase 3Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06533384 · CT.gov ↗
What to watch
2027 (33)
January 2027 (2)
Phase 2Metastatic Pancreatic CarcinomaNot yet recruiting
Est. primary completion 2027-01-15 · NCT06759090 · CT.gov ↗
What to watch
Phase 2Unresectable Metastatic Rectal Cancer, CAPOX, Combination of RadioimmunotherapyNot yet recruiting
Est. primary completion 2027-01-30 · NCT07059949 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Advanced Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03-31 · NCT06632405 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-03-31 · NCT07618546 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Germline BRCA-mutated HER2-negative Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05576389 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-01 · NCT05738616 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Triple Negative Breast Cancer (TNBC), Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT06731153 · CT.gov ↗
What to watch
July 2027 (1)
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT05772273 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07100392 · CT.gov ↗
What to watch
Phase 2Mixed Hepatocellular-cholangiocarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07105748 · CT.gov ↗
What to watch
September 2027 (2)
Early phase / not applicableTNBCNot yet recruiting
Est. primary completion 2027-09-15 · NCT07491822 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07627620 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Rectal CancerRecruiting
Est. primary completion 2027-10-01 · NCT06229041 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Esophageal Squamous Cell CarcinomaEnrolling by invitation
Est. primary completion 2027-11-01 · NCT07312578 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-11-20 · NCT06669611 · CT.gov ↗
What to watch
December 2027 (15)
Phase 2Esophageal Squamour Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07191977 · CT.gov ↗
What to watch
Phase 2Endometrioid Endometrial CancerRecruiting
Est. primary completion 2027-12-01 · NCT06561308 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-22 · NCT07016126 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2027-12-30 · NCT07334483 · CT.gov ↗
What to watch
Phase 2Refractory Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-12-30 · NCT07896096 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Advanced Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response, ChemotherapyRecruiting
Est. primary completion 2027-12-31 · NCT06811844 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07154082 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07314372 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07555860 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Unresectable Gallbladder CancerRecruiting
Est. primary completion 2027-12-31 · NCT06423170 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (19)
January 2028 (2)
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT06196671 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT07324473 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2028-02-01 · NCT07527026 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-02-20 · NCT06796803 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Breast Cancer Triple Negative Breast CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT07471815 · CT.gov ↗
What to watch
Phase 2Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, CamrelizumabRecruiting
Est. primary completion 2028-03-31 · NCT07787273 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2/3Metastatic Pancreatic CancerRecruiting
Est. primary completion 2028-05-31 · NCT06361888 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder CancerNot yet recruiting
Est. primary completion 2028-06-05 · NCT07639983 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1/2Head and Neck CancerRecruiting
Est. primary completion 2028-07-01 · NCT07662681 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-07-31 · NCT06172205 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT04803539 · CT.gov ↗
What to watch
December 2028 (7)
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2028-12-31 · NCT07505186 · CT.gov ↗
What to watch
Phase 2Late-stage Resectable Esophageal Squamous CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07622797 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07902713 · CT.gov ↗
What to watch
Phase 2/3HCCRecruiting
Est. primary completion 2028-12-31 · NCT07589244 · CT.gov ↗
What to watch
Phase 3Breast Cancer Stage IV, Triple -Negative Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch
Phase 3Resectable Esophageal Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-12-31 · NCT05043688 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07790419 · CT.gov ↗
What to watch
2029 (7)
January 2029 (2)
Phase 3Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07948317 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01-15 · NCT07328009 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity NeoplasmNot yet recruiting
Est. primary completion 2029-02 · NCT07400094 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal Cancer (CRC)Not yet recruiting
Est. primary completion 2029-02-01 · NCT07395063 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Hepato Cellular Carcinoma (HCC), Chemotherapy EffectRecruiting
Est. primary completion 2029-10 · NCT07267806 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1/2Liver CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07587034 · CT.gov ↗
What to watch
Phase 2Esophageal CancerRecruiting
Est. primary completion 2029-12-31 · NCT06869226 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Early phase / not applicableCervical CancerNot yet recruiting
Est. primary completion 2030-04-01 · NCT07466901 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT06739317 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07432087 · CT.gov ↗
What to watch
2031 (3)
March 2031 (1)
Phase 2/3Cervical CancerRecruiting
Est. primary completion 2031-03-01 · NCT06288373 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-04-10 · NCT06992336 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Rectal Cancer PatientsNot yet recruiting
Est. primary completion 2031-12-31 · NCT07521605 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 1/2Breast NeoplasmsRecruiting
Est. primary completion 2032-04-30 · NCT05981001 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

9 April 2027FDA action datePDUFA target action date for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Source ↗

Recent

5 November 2026Filing acceptedFDA accepts the resubmitted rivoceranib + camrelizumab applications (first-line uHCC)
US, FDA · Source ↗
10 July 2026Complete response letterFDA issues complete response letter for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗